These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6347481)

  • 1. Therapeutic use of TP5 (thymopoietin 32-36) in sarcoidosis of the skin.
    Thivolet J; Faure M; Nicolas JF; Mauduit G; Claudy A
    Clin Immunol Immunopathol; 1983 Mar; 26(3):350-60. PubMed ID: 6347481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abrogation of in vitro suppressor cell activity in adult common variable hypogammaglobulinemia after TP5 treatment.
    Williams RC; Montano JD; Bankhurst AD
    J Lab Clin Med; 1983 Jan; 101(1):152-60. PubMed ID: 6217268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Model for acquired immunodeficiency caused by anesthesia and surgical procedures. Effect of treatment with thymopoietin pentapeptide (TP5)].
    Auteri A; D'Aniello C; Falotico N; Saletti M; Di Perri T
    Recenti Prog Med; 1986 Sep; 77(9):423-8. PubMed ID: 3541085
    [No Abstract]   [Full Text] [Related]  

  • 4. Studies of thymopoietin pentapeptide (TP5) on experimental tumors. I. TP5 relieves immunosuppression in tumor-bearing mice.
    Lau CY; Wang EY; Goldstein G
    Cell Immunol; 1982 Jan; 66(2):217-32. PubMed ID: 6802504
    [No Abstract]   [Full Text] [Related]  

  • 5. Thymopoietin pentapeptide treatment of primary immunodeficiencies.
    Aiuti F; Businco L; Fiorilli M; Galli E; Quinti I; Rossi P; Seminara R; Goldstein G
    Lancet; 1983 Mar; 1(8324):551-4. PubMed ID: 6131256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of cutaneous T-cell lymphomas with TP-5. Evaluation of the clinical effect in 8 patients.
    Przybilla B; Burg G; Schmoeckel C; Braun-Falco O
    Acta Derm Venereol; 1983; 63(6):524-9. PubMed ID: 6198843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normalization of the CD4/CD8 lymphocyte ratio and increased B lymphocytes in long standing diabetic patients following therapy with thymopentin.
    Pozzilli P; Visalli N; Cavallo MG; Beales P; Negri M; Ghirlanda G; Papa V; Andreani D
    Diabetes Res; 1987 Oct; 6(2):51-6. PubMed ID: 2962799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy with thymopoietin pentapeptide (TP-5) in 26 patients with primary immunodeficiencies.
    Aiuti F; Businco L; Fiorilli M; Galli E; Quinti I; Le Moli S; Seminara R; Goldstein G
    Birth Defects Orig Artic Ser; 1983; 19(3):267-72. PubMed ID: 6360238
    [No Abstract]   [Full Text] [Related]  

  • 9. FcIgG receptor-bearing lymphocytes and monoclonal antibody-defined T cell subsets in atopic dermatitis: effect of treatment with thymopoietin pentapeptide (TP-5).
    Strannegård O; Strannegård IL; Kang K; Cooper KD; Hanifin JM
    Int Arch Allergy Appl Immunol; 1982; 69(3):238-44. PubMed ID: 6752042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of synthetic thymic hormone (TP5) in children with T-cell immunodeficiencies.
    Levinsky RJ; Davies EG; Goldstein G
    Birth Defects Orig Artic Ser; 1983; 19(3):273-6. PubMed ID: 6360239
    [No Abstract]   [Full Text] [Related]  

  • 11. Thymopentin administration and increase of sero-conversion after B-hepatitis vaccine in diabetic patients.
    Pagani S; Cruciani L; Chianelli M; Procaccini E; Pozzilli P
    Diabetes Res; 1989 Dec; 12(4):199-201. PubMed ID: 2534655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymopoietin pentapeptide (thymopentin, TP-5) in the treatment of rheumatoid arthritis. A compilation of several short- and longterm clinical studies.
    Veys EM; Mielants H; Verbruggen G; Spiro T; Newdeck E; Power D; Goldstein G
    J Rheumatol; 1984 Aug; 11(4):462-6. PubMed ID: 6384507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Numeration of T cell subsets in sarcoidosis using monoclonal antibodies: decreased levels of peripheral blood T cells and cells with suppressor T cell phenotype.
    Faure M; Nicolas JF; Gaucherand M; Czernielewski J; Mauduit G; Thivolet J
    Dermatologica; 1982 Aug; 165(2):88-93. PubMed ID: 6216129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulation of cellular function by thymopentin (TP-5) in three AIDS patients.
    Mascart-Lemone F; Huygen K; Clumeck N; Brenez D; Bolla K; Duchateau J
    Lancet; 1983 Sep; 2(8352):735-6. PubMed ID: 6193382
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of recurrent herpes simplex with thymopoietin-pentapeptide].
    Djawari D; Bolla K; Haneke E
    Dtsch Med Wochenschr; 1984 Mar; 109(13):496-8. PubMed ID: 6368167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymopentin in chronic Trichophyton rubrum infection.
    Molin L; Bolla K
    Surv Immunol Res; 1985; 4 Suppl 1():135-8. PubMed ID: 3898286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results in two infants with the DiGeorge syndrome--effects of long-term TP5.
    Businco L; Rubaltelli FF; Paganelli R; Galli E; Ensoli B; Betti P; Aiuti F
    Clin Immunol Immunopathol; 1986 May; 39(2):222-30. PubMed ID: 3084141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymopentin treatment in a patient with pluriorificial pyoderma vegetans.
    Simon M; Djawari D; Horstein OP; Bolla K
    Surv Immunol Res; 1985; 4 Suppl 1():125-8. PubMed ID: 3898284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunomodulating therapy in chronic polyarthritis with thymopentin. A multicenter placebo-controlled study of 119 patients].
    Lemmel EM; Bach GL; Bolten W; Brackertz D; Fahmy Z; Mattern H; Stroehmann I; Wittenborg A
    Dtsch Med Wochenschr; 1988 Feb; 113(5):172-6. PubMed ID: 3276492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymopoietin pentapeptide treatment of sarcoidosis.
    Thivolet J; Faure M
    J Am Acad Dermatol; 1983 Nov; 9(5):773-4. PubMed ID: 6643779
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.